Laboratory techniques

Comparison of six commercial enzyme linked immunosorbent assays for detecting IgM antibodies against Toxoplasma gondii

C VERHOFSTEDE, L VAN RENTERGHEM, J PLUM  Department of Medical Microbiology, University Hospital, Gent, Belgium

SUMMARY To evaluate the usefulness of different commercial enzyme linked immunosorbent assays (ELISAs) for the detection of IgM antibodies against Toxoplasma gondii the results of six of these assays for a panel of 81 sera were compared. The following tests were selected: Toxoplasma gondii IgM ELISA (Clark Laboratories), Toxoplasma IgM EIA (Labsystems), Toxo-M EIA (Abbott), Toxonostika M (Organon), Toxo M Enzyme Immunoassay (Hybritech) and Platelia Toxo IgM (Diagnostics Pasteur). An antibody capture ELISA developed at our laboratory was used as the reference test. An IgM immunoblotting assay was also performed. Four (Toxoplasma IgM EIA, Toxo-M EIA, Toxonostika M, and Platelia Toxo IgM) of the commercial IgM ELISAs gave a high sensitivity and a high specificity. Toxo-M EIA, Toxonostika M, Toxoplasma IgM EIA and the Toxo M Enzyme Immunoassay were too insensitive, and the Toxoplasma gondii IgM ELISA was both insensitive and unspecific. No remarkable differences were observed between the results of indirect or antibody capture ELISAs, and between the results of ELISAs performed with polyclonal or monoclonal antibodies.

Diagnosis of acquired Toxoplasma gondii infection is usually based on the serological demonstration of IgG or IgM antibodies. Since the first description of a microplate enzyme linked immunosorbent assay (ELISA) by Voller et al, the ELISA has become an increasingly popular procedure for the detection of T gondii specific antibodies. The ELISA for IgG antibody detection is already well accepted in most routine laboratories. Commercial ELISAs for IgM antibody detection, on the other hand, have only recently become available. The development of an IgM ELISA has posed some problems, and the search for an improvement in the specificity and sensitivity of the technique has resulted in a broad range of different test systems: both indirect ELISAs and antibody capture ELISAs have been developed. Antibody capture ELISAs are performed with either polyclonal or monoclonal antibodies. This study aimed at evaluating the usefulness of different commercial ELISAs for IgM detection. The results of six of them for a panel of 81 sera were compared. An antibody capture ELISA developed at our laboratory was used as a reference test to select and group the tested sera. An immunoblotting assay for the detection of IgM antibodies was used as an additional technique in cases in which discordant ELISA results were found.

Material and methods

COMMERCIAL TESTS

Toxoplasma gondii IgM ELISA (Clark Laboratories Inc., Jamestown, New York)

The principle of this test is based on an indirect solid phase enzyme immunoassay. The procedure is carried out in three basic reaction steps. Ninety six well 12 x 8 strip polystyrene microtiter plates are coated alternately with toxoplasma antigen and control antigen. After the patient’s serum has been incubated horse-radish peroxidase conjugated anti-human IgM is added. Peroxidase activity is detected using o-phenylenediamine (OPD) and hydrogen peroxide. The colour intensity is determined in a spectrophotometer at 492 nm. Control well absorbance is substracted from antigen well absorbance for each sample. Potential interference from such factors as rheumatoid factor are averted by treating serum samples with goat anti-human IgG before running the assay. The overall incubation time for this assay is one hour and 10 minutes.

Toxoplasma IgM EIA (Labsystems, Helsinki, Finland)

The principle of the Labsystems ELISA is similar to that of the Clark ELISA. Toxoplasma antigens are
coated on the polystyrene surface of a 96-well 12 × 8 strip microtitre plate. After incubation of the patient’s serum sample, alkaline phosphatase conjugated anti-human IgM is added. Phosphatase activity is detected using p-nitrophenylphosphate (PNPP). The colour intensity is determined at 405 nm. The overall incubation time for this assay is two hours and 45 minutes. Serum samples are treated with rheumatoid factor absorbent purchased from Behringwerke (Marburg, West Germany) in order to minimise rheumatoid factor interference.

**Toxo-M EIA** (Abbott, North Chicago, Illinois)

This is an ELISA based on an antibody capture principle. The patient’s serum sample is incubated with a polystyrene bead coated with anti-human IgM. A complex of toxoplasma antigen, rabbit antitoxoplasma IgG, and horseradish peroxidase is then added to the bead. Peroxidase activity is detected using OPD and hydrogen peroxide. The overall incubation time of this assay is three and a half hours.

**Toxonostika M** (Organon Technika, Boxtel, The Netherlands)

The principle of this test is similar to that of the Abbott ELISA but the Organon ELISA is performed in 96-well 8 × 12 microtitre plates. The wells of the plate are coated with sheep antibodies to human IgM. After the patient’s serum has been incubated a mixture of toxoplasma antigen and sheep antitoxoplasma antibodies, which have been labelled with horseradish peroxidase, is added. Peroxidase activity is detected using tetramethylbenzidine (TMB) and urea peroxide. Absorbances are read at 405 nm. The overall incubation time is two and a half hours.

**Toxo M Enzyme Immunoassay** (Hybritech Europe, Liège, Belgium)

The principle of the Hybritech ELISA is similar to that of the Abbott ELISA. The patient’s serum is incubated with a plastic bead coated with monoclonal anti-human IgM. A complex of toxoplasma antigen, antitoxoplasma IgG, and alkaline phosphatase is then added to the bead. Phosphatase activity is detected using PNPP. Absorbances are read at 405 nm. The overall incubation time is two and half hours.

**Platelia Toxo IgM** (Diagnostics Pasteur, Marnes-la-Coquette, France)

This ELISA is also based on an antibody capture principle. The wells of a 96-well 6 × 16 strip microtitre plate coated with anti-human IgM are incubated with patient’s serum. A mixture of toxoplasma antigen and antitoxoplasma monoclonal antibody labelled with peroxidase is added to the wells. The presence of peroxidase is detected by the addition of OPD and hydrogen peroxide. The overall incubation time is three hours.

All tests were obtained commercially and performed by the same technician according to the manufacturer’s instructions. For each kit all determinations were done in the same run.

**REFERENCE ELISA**

The antibody capture ELISA developed at our laboratory is performed as described by Duermeyer et al with slight modifications. Briefly, 96-well microtitre plates (Immunoplate I, Nunc, Roskilde, Denmark) are coated overnight with goat anti-human IgM antibodies (Tago Inc., Burlingame, California) at 2 μg protein/ml carbonate buffer, pH 9.6. After washing with phosphate buffered saline (PBS) containing 0.05% Tween-20 (PBS-T) a 1/200 dilution in PBS-T of the sera to be tested is added to duplicate wells and incubated at room temperature for one hour. Plates are then washed with PBS-T. Toxoplasma antigen is diluted 1/200 in PBS-T and is added to one of the wells. The other well is filled with PBS-T as a blank control. Plates are incubated for one hour at room temperature and then washed again. Rabbit antitoxoplasma serum (1/100000 in PBS-T) is added to all wells. The plates are washed after one hour, and goat anti-rabbit peroxidase conjugate (Tago) (1/5000 in PBS-T) is added and incubated at room temperature for one hour. The plates are washed again and the amount of bound enzyme is measured with OPD and hydrogen peroxide as the substrate. The reaction is stopped after 20 minutes by adding 4 N H₂SO₄ and the optical density is read at 492 nm. Blank control readings are subtracted from the readings obtained with antigen. Reference positive and negative sera are tested on each plate to define the cut-off value.

**Toxoplasma antigen used in the reference ELISA**

Toxoplasma trofozoites are cultivated in human larynx carcinoma cells (Hep-2) as described previously. After passing through a 3 μm pore size polycarbonate filter (Nucleopore Corporation, Pleasanton, California) to eliminate contaminating cells the purified organisms are pelleted (2000 × g, 10 minutes) and resuspended in distilled water to a concentration of 1 × 10⁶ trofozoites/ml. This suspension is then sonicated five times for one minute at 50 watts, and to each ml of sonicate 30 μl 37% formaldehyde is added. Preliminary tests have indicated that treating the antigen in this way leads to an important reduction of non-specific binding in the IgM-ELISA. The antigen preparation can be stored at 4°C for a period of at least six months.

**IMMUNOBLOTTING ASSAY**

An antigen preparation containing 2 × 10⁶ purified
Comparison of six ELISAs that detect *T. gondii* antibodies

Table 1  IgM results of six commercial ELISAs and reference ELISA for seven follow up sera from patient with acute *T. gondii* infection

<table>
<thead>
<tr>
<th>Date of blood collection</th>
<th>Reference ELISA</th>
<th>Abbott</th>
<th>Organon</th>
<th>Pasteur</th>
<th>Labsystems</th>
<th>Hybritech</th>
<th>Clark Laboratories</th>
</tr>
</thead>
<tbody>
<tr>
<td>24/10/85</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>26/11/85</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>06/02/86</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>04/05/86</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>02/01/87</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>04/05/87</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>26/11/87</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Trophozoites/ml was electrophoresed in polyacrylamide slab gels using a discontinuous sodium dodecyl sulphate (SDS) buffer system as described by Laemmli with a 15% running gel and a 4-75% stacking gel. Proteins were transferred from the SDS slab gel to a polyvinylidene difluoride membrane (Immobilion PVDF, Millipore, Bedford, Massachusetts) using the method of Towbin et al. After the transfer the PVDF membrane was soaked in PBS + 0.5% Tween-20 (PBS-T) for one hour to saturate additional protein binding sites. Subsequently, the PVDF strips were incubated with a 1/400 dilution of human serum in PBS-T containing 5% non-fat dry milk and thereafter with a 1/1000 dilution of alkaline phosphatase conjugated goat anti-human IgM (Sigma Chemical Co, St Louis, Missouri).

The alkaline phosphatase activity was detected by the method of Blake et al., using 5-bromo-4-chloroindolyl phosphate and nitro blue tetrazoliumchloride. According to Sharma et al., Ptasman et al. and Herbink et al., sera with a clear reaction against the low molecular weight component (± 6 kilodaltons) of toxoplasma were considered to be positive for the presence of specific IgM antibodies.

**SERA**

A total of 81 sera sent to our laboratory to be tested for the presence of toxoplasma antibodies were used for serological comparison. The serum samples were classified in different series.

**Series A** consisted of seven follow up sera from a single patient with an acute toxoplasma infection. The sera were taken from one week after onset of clinical symptoms, and over a period of two years.

**Series B** consisted of 10 sera from patients with no evidence of a recent toxoplasmosis but with antiviral IgM antibodies detectable in their sera. This group included the serum of two patients with hepatitis A, one with rubella, one with measles, one with mumps, one with herpes simplex, two with cytomegalovirus and two with Epstein Barr virus IgM antibodies.

**Series C** consisted of 10 sera from rheumatoid factor positive patients. Four of these patients also had antinuclear antibodies.

**Series D** consisted of 28 sera from patients with toxoplasma specific IgM antibodies as defined in the reference ELISA. A recent toxoplasmosis in these patients was further confirmed by a rise in IgG in subsequent samples or the presence of clinical symptoms.

**Series E** consisted of 14 sera from patients with lymphadenopathy but with no detectable IgM antibodies to toxoplasma in the reference ELISA.

**Series F** consisted of 12 sera from pregnant women without clinical symptoms suggesting a recent infection, without detectable IgM antibodies in the reference ELISA, and for whom toxoplasma specific IgG titres remained constant for a period of over at least one month.

There was no significant difference between the age distribution and the amount of toxoplasma specific IgG antibodies for the patients in series B, C, E and F.

**Results**

Table 1 shows the ELISA results of the follow up sera from a recently infected patient (sera of series A). In three ELISAs (Abbott, Pasteur, and Labsystems) IgM antibodies were detected during the entire follow up period of two years. The ELISA of Hybritech, on the other hand, already gave negative results four to seven months after the first sample had been taken.

Table 2 summarises the results for the sera of series B to F. None of the sera with antiviral IgM antibodies (series B) gave a positive result in any of the commercial ELISAs. In the reference ELISA one serum, containing hepatitis A virus IgM antibodies, was positive. This serum was clearly negative in immunoblotting.

With exception of the Hybritech ELISA, all tests gave positive results for one or two sera positive for rheumatoid factor (series C). One of these positive patients gave a positive or equivocal result in four of the six commercial ELISAs (Abbott, Clark Laboratories, Labsystems, Pasteur), and in the reference ELISA. This serum was also positive by immunoblotting, suggesting that this patient still had low toxoplasma specific IgM antibody titres due to a recent
infection. In the Organon ELISA two other patients positive for rheumatoid factor were reported positive. One of these patients was also positive in the Clark Laboratories ELISA. None of these patients was found to be positive by immunoblotting.

All the 28 sera from patients with a recent toxoplasmosis were found to be positive by immunoblotting and in four of the six commercial ELISAs (Abbott, Labsystems, Organon, Pasteur). The ELISAs of Hybritech and Clark Laboratories, on the other hand, only detected antibodies in, respectively, 19 and 25 of these sera.

All the 14 sera from patients with lymphadenopathy but with a negative result in the reference ELISA (sera of series E), were also found to be negative in four of the six commercial ELISAs (Abbott, Hybritech, Labsystems, and Organon). The Pasteur ELISA gave a weakly positive result for one patient. Another patient was clearly found to be positive in the Clark Laboratories ELISA. These patients were found to be negative by immunoblotting.

Only two of the six commercial ELISAs reported as negative all of the 12 sera from pregnant women who had no indications of a recent infection and were found to be negative in the reference ELISA (series F).

In the four other tests positive or equivocal results were found. The ELISA results and immunoblotting results of series F are summarised in table 3.

**Discussion**

The number of available commercial ELISA tests for the detection of toxoplasma specific IgM antibodies has increased considerably in recent years. To evaluate the usefulness of some of these commercial tests we compared the results of six of them for 81 carefully selected sera. For the selection of sera an antibody-capture ELISA developed at our laboratory was used as the reference test.

The studies of Sharma et al, Potasman et al, and Herbrink et al, have shown that recognition of a 6 kilodalton antigen in immunoblotting is highly correlated with detection of IgM antitoxoplasma antibodies in ELISA.15-17 An immunoblotting assay was therefore performed as an additional control test. Detailed studies concerning the diagnostic importance of immunoblotting compared with ELISA are, however, not yet available.

The overall agreement between four of the six
Comparison of six ELISAs that detect T gondii antibodies

Commercial ELISAs (Abbott, Labsystems, Organon, and Pasteur), and between these tests and the reference ELISA was good. No remarkable differences were observed between the results of indirect ELISAs (Labsystems, Clark Laboratories) or antibody capture ELISAs, between the results of ELISAs performed with monoclonal (Hybritech, Pasteur) or polyclonal antibodies, or between the ELISAs performed on coated beads (Abbott, Hybritech) or in microtitre plates. The Clark Laboratories ELISA was the most rapid test (one hour and 10 minutes of incubation), the ELISA of Abbott was the most time consuming (three and a half hours of incubation). All six assays had a comparable handling ease.

Commercial IgM ELISAs were able to detect antibodies for either a long (Abbott, Labsystems, Pasteur) or short (Hybritech, Clark Laboratories) period after a recent T gondii infection, reflecting a higher or lower sensitivity of the test. This observation might indicate that a positive result in tests with a lower sensitivity correlates better with the recent stage of infection and that these tests are therefore more useful for the diagnosis of acute toxoplasmosis. One must be aware, however, of the fact that large individual variations in IgM response can exist and that a recent T gondii infection can be accompanied by either a high or a low IgM response. The use of tests with a low sensitivity may mean that diagnosis can be missed in those patients in whom IgM production is low.

Only the ELISAs of Abbott, Labsystems, Organon and Pasteur detected antibodies in all of the 28 sera from patients with confirmed acute infection. With the Clark Laboratories ELISA and the ELISA of Hybritech the diagnosis was missed in respectively three and nine of them, again reflecting the lower sensitivity of the latter tests.

Only the ELISAs of Abbott, Organon, and Hybritech did not give false positive results in the group of 36 patients with no evidence of a recent T gondii infection (series B, E, and F). Two of these patients, with a positive result in the immunoblotting assay, were assumed to possess low titres of IgM antibodies at rest. False positive or doubtful results were common in the Clark Laboratories ELISA (five of 36), but were also seen in the Labsystems ELISA (two of 36), and that of Pasteur (two of 36).

False positive results were more common in the group of pregnant women than in the series of patients with adenopathy or with antiviral IgM antibodies. The reason for this discrepancy in the number of false positive results is unclear.

The presence of rheumatoid factor is seen as one of the most important sources of false positive results in the IgM detection systems. Interference of rheumatoid factor in the indirect ELISA without pre-treatment of the sera has been clearly shown. The presence of rheumatoid factor interference in the antibody capture ELISA is still a matter of controversy. In our study only the Organon ELISA, which is an antibody capture ELISA, showed pronounced rheumatoid factor interference. These findings contrast with the results of Joyson et al, who found rheumatoid factor interference in the Abbott ELISA but not in the test of Organon. Interference with antiviral IgM antibodies was not demonstrable in any of the commercial ELISAs.

In conclusion, the IgM ELISAs of Abbott, Labsystems, and Pasteur have a high sensitivity and a high specificity, although in the ELISAs of Labsystems and Pasteur false positive results cannot be ruled out completely. The Organon ELISA can also be seen as a useful test, although it is less sensitive and the user has to be aware of possible rheumatoid factor interference. We found that the Hybritech ELISA is too insensitive and that the Clark Laboratories ELISA is both insensitive and unspecific.

References


Requests for reprints to: Dr C Verhofstede, Department of Medical Microbiology, University Hospital, De Pintelaan 185, 9000 Gent, Belgium.